This company listing is no longer active
Destiny Pharma Yönetim
Yönetim kriter kontrolleri 3/4
Destiny Pharma's CEO is Chris Tovey, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is £123.00K, comprised of 89.4% salary and 10.6% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth £1.90K. The average tenure of the management team and the board of directors is 3.4 years and 6.3 years respectively.
Anahtar bilgiler
Chris Tovey
İcra Kurulu Başkanı
UK£123.0k
Toplam tazminat
| CEO maaş yüzdesi | 89.4% |
| CEO görev süresi | less than a year |
| CEO sahipliği | 0.04% |
| Yönetim ortalama görev süresi | 3.4yrs |
| Yönetim Kurulu ortalama görev süresi | 6.3yrs |
Son yönetim güncellemeleri
Recent updates
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Jan 12
Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans
Sep 26We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully
May 26Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth
Feb 01Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?
Aug 05Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Apr 16What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?
Feb 11
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Nov 30CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Dec 31 2023 | UK£123k | UK£110k | -UK£6m |
Tazminat ve Piyasa: Chris's total compensation ($USD158.25K) is below average for companies of similar size in the UK market ($USD361.35K).
Tazminat ve Kazançlar: Insufficient data to compare Chris's compensation with company performance.
CEO
Chris Tovey (59 yo)
less than a year
Görev süresi
UK£123,000
Tazminat
Mr. Christopher John Tovey, also known as Chris, BSc, serves as Chief Executive Officer & Director of Destiny Pharma plc since September 1, 2023. He had been the Chief Operating Officer at GW Pharmaceutica...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | less than a year | UK£123.00k | 0.042% £ 1.9k | |
| Founder | 27.6yrs | UK£250.00k | 6.8% £ 309.2k | |
| CFO, Company Secretary & Director | 5.8yrs | UK£270.00k | 0.025% £ 1.2k | |
| Interim CMO & Senior Independent Director | less than a year | UK£213.00k | 0.092% £ 4.2k |
3.4yrs
Ortalama Görev Süresi
60.5yo
Ortalama Yaş
Deneyimli Yönetim: DEST's management team is considered experienced (3.4 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | less than a year | UK£123.00k | 0.042% £ 1.9k | |
| Founder | no data | UK£250.00k | 6.8% £ 309.2k | |
| CFO, Company Secretary & Director | 5.8yrs | UK£270.00k | 0.025% £ 1.2k | |
| Interim CMO & Senior Independent Director | 4.6yrs | UK£213.00k | 0.092% £ 4.2k | |
| Independent Chairman | 8yrs | UK£34.00k | 3.93% £ 178.7k | |
| Member of Scientific Advisory Board | 6.3yrs | Veri yok | Veri yok | |
| Non-Executive Director | 2.2yrs | UK£41.00k | 0.36% £ 16.6k | |
| Member of Scientific Advisory Board | 6.3yrs | Veri yok | Veri yok | |
| Chair of the Scientific Advisory Board | 6.3yrs | UK£10.66k | Veri yok | |
| Member of Scientific Advisory Board | 6.3yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 6.3yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
6.3yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: DEST's board of directors are considered experienced (6.3 years average tenure).